Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Methylation of the retinoblastoma tumor suppressor by SMYD2.

http://www.ncbi.nlm.nih.gov/pubmed/20870719

The retinoblastoma tumor suppressor (RB) is a central cell cycle regulator and tumor suppressor. RB cellular functions are known to be regulated by a diversity of post-translational modifications such as phosphorylation and acetylation, raising the possibility that RB may also be methylated in cells. Here we demonstrate that RB can be methylated by SMYD2 at lysine 860, a highly conserved and novel site of modification. This methylation event occurs in vitro and in cells, and it is regulated during cell cycle progression, cellular differentiation, and in response to DNA damage. Furthermore, we show that RB monomethylation at lysine 860 provides a direct binding site for the methyl-binding domain of the transcriptional repressor L3MBTL1. These results support the idea that a code of post-translational modifications exists for RB and helps guide its functions in mammalian cells.

Pubmed ID: 20870719 RIS Download

Mesh terms: Amino Acid Motifs | Amino Acid Sequence | Cell Line, Tumor | Gene Expression Regulation | Histone-Lysine N-Methyltransferase | Humans | Methylation | Molecular Sequence Data | Nuclear Proteins | Protein Binding | Retinoblastoma Protein | Sequence Alignment | Transcription Factors

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIA NIH HHS, Id: F30 AG034741
  • Agency: NCRR NIH HHS, Id: P41 RR011823
  • Agency: NCI NIH HHS, Id: R01 CA132685
  • Agency: NCI NIH HHS, Id: T32 CA009302
  • Agency: NCI NIH HHS, Id: T32 CA009523

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.